临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2013年
6期
504-506
,共3页
双相情感障碍%抑郁发作%喹硫平%碳酸锂%汉密顿抑郁量表%副反应量表
雙相情感障礙%抑鬱髮作%喹硫平%碳痠鋰%漢密頓抑鬱量錶%副反應量錶
쌍상정감장애%억욱발작%규류평%탄산리%한밀돈억욱량표%부반응량표
Bipolar affective disorder%depressive episode%quetiapine%lithium carbonate%HAMD%TESS
目的:探讨喹硫平治疗双相情感障碍抑郁发作的临床疗效和安全性。方法将66例双相情感障碍抑郁发作患者随机分为两组,研究组口服喹硫平治疗,对照组口服喹硫平联合碳酸锂治疗,观察8周。治疗前后采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果对照组治疗第1周、2周、4周末汉密顿抑郁量表评分较研究组下降更显著( P<0.05或0.01);治疗8周末,研究组显效率75.0%、总有效率93.8%,对照组为76.7%、96.7%,两组疗效比较差异无显著性(P>0.05)。研究组总体不良反应发生率显著低于对照组(P<0.05)。结论喹硫平治疗双相情感障碍抑郁发作疗效显著,虽没有喹硫平联合碳酸锂治疗起效快,但总体疗效相当,且安全性更高,依从性更好。
目的:探討喹硫平治療雙相情感障礙抑鬱髮作的臨床療效和安全性。方法將66例雙相情感障礙抑鬱髮作患者隨機分為兩組,研究組口服喹硫平治療,對照組口服喹硫平聯閤碳痠鋰治療,觀察8週。治療前後採用漢密頓抑鬱量錶評定臨床療效,副反應量錶評定不良反應。結果對照組治療第1週、2週、4週末漢密頓抑鬱量錶評分較研究組下降更顯著( P<0.05或0.01);治療8週末,研究組顯效率75.0%、總有效率93.8%,對照組為76.7%、96.7%,兩組療效比較差異無顯著性(P>0.05)。研究組總體不良反應髮生率顯著低于對照組(P<0.05)。結論喹硫平治療雙相情感障礙抑鬱髮作療效顯著,雖沒有喹硫平聯閤碳痠鋰治療起效快,但總體療效相噹,且安全性更高,依從性更好。
목적:탐토규류평치료쌍상정감장애억욱발작적림상료효화안전성。방법장66례쌍상정감장애억욱발작환자수궤분위량조,연구조구복규류평치료,대조조구복규류평연합탄산리치료,관찰8주。치료전후채용한밀돈억욱량표평정림상료효,부반응량표평정불량반응。결과대조조치료제1주、2주、4주말한밀돈억욱량표평분교연구조하강경현저( P<0.05혹0.01);치료8주말,연구조현효솔75.0%、총유효솔93.8%,대조조위76.7%、96.7%,량조료효비교차이무현저성(P>0.05)。연구조총체불량반응발생솔현저저우대조조(P<0.05)。결론규류평치료쌍상정감장애억욱발작료효현저,수몰유규류평연합탄산리치료기효쾌,단총체료효상당,차안전성경고,의종성경호。
Objective To explore the efficacy and safety of quetiapine in the treatment of depressive phase of bipolar affective disorder .Methods Sixty-six patients with depressive phase of bipolar affective disorder were randomly assigned to research group taking orally quetiapine and control group doing quetiapine plus lithium carbonate for 8 weeks . Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) before and after treatment .Results At the end of the 1st ,2nd and 4th week the HAMD scores lowered more significantly in control than research group (P<0 .05 or 0 .01);at the end of the 8th week obvious and total rate were re-spectively 75 .5% and 93 .8% in research and 76 .7% and 96 .7% in control group ,which showed no signif-icant differences (P>0 .05) .Total incidence of adverse reactions was significantly lower in research than control group (P<0 .05) .Conclusion Quetiapine has an evident effect in depressive phase of bipolar af-fective disorder ,it takes effect slower than quetiapine plus lithium carbonate does ,but their total efficacy are equivalent ,the former has higher safety and better compliance .